FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025329937> ?p ?o ?g. }

• W2025329937 endingPage "433" @default.
• W2025329937 startingPage "427" @default.
• W2025329937 abstract "The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors, and its role in adipogenesis and glucose metabolism has been well established. PPAR-gamma agonists have been shown to inhibit many cytokines and to have anti-inflammatory effects. In pathologic conditions, enhanced fluoro-2-deoxy-D-glucose (FDG) uptake is observed not only in malignant tumors but also in inflammatory lesions, and this uptake occurs through the glucose transporter in these cells. Thus, the present study was undertaken to investigate the potential of using PPAR-gamma's glucose uptake ability as a diagnostic tool to differentiate between macrophage and tumor cells.Cellular uptake studies were carried out on macrophage and two tumor cell lines for comparison by using (18)F-FDG. Western blot analysis was performed to determine the expression levels of both the glucose transporter and hexokinase protein. To confirm the possibility of differentiation between tumor and inflammatory lesions using rosiglitazone based on in vitro studies, (18)F-FDG (3.7 x 10(6) Bq) uptake in A549 and RAW 264.7 xenograft mice was compared.The cellular uptake study findings were quite different for macrophages and tumor cells. (18)F-FDG uptakes by macrophages decreased by about 60% but was increased twofold in tumor cells after rosiglitazone treatment. Moreover, the expressions of proteins related to glucose uptake correlated well with cellular glucose accumulation in both cell types. Higher tumor uptake was observed after the injection of rosiglitazone in A549 xenograft mice (1.58+/-0.55 to 4.66+/-1.16), but no significant change of (18)F-FDG uptake was shown in RAW 264.7 xenograft mice (4.04+/-1.16 to 4.00+/-0.14).The present study demonstrates the roles of PPAR-gamma agonist on FDG uptake in macrophages and tumor cells in vitro and in vivo. Our findings suggest that rosiglitazone has the potential to increase the contrast between tumor and inflammatory lesions." @default.
• W2025329937 created "2016-06-24" @default.
• W2025329937 creator A5001737851 @default.
• W2025329937 creator A5006339259 @default.
• W2025329937 creator A5011091703 @default.
• W2025329937 creator A5033467158 @default.
• W2025329937 creator A5045566016 @default.
• W2025329937 creator A5079729400 @default.
• W2025329937 creator A5082078967 @default.
• W2025329937 creator A5086691038 @default.
• W2025329937 creator A5002173683 @default.
• W2025329937 date "2009-05-01" @default.
• W2025329937 modified "2023-10-01" @default.
• W2025329937 title "The effect of PPAR-γ agonist on 18F-FDG uptake in tumor and macrophages and tumor cells" @default.
• W2025329937 cites W125577685 @default.
• W2025329937 cites W1511195742 @default.
• W2025329937 cites W1522571942 @default.
• W2025329937 cites W1580962701 @default.
• W2025329937 cites W1583731895 @default.
• W2025329937 cites W1608005125 @default.
• W2025329937 cites W1633340712 @default.
• W2025329937 cites W1965504530 @default.
• W2025329937 cites W1966099909 @default.
• W2025329937 cites W1971341208 @default.
• W2025329937 cites W1978380407 @default.
• W2025329937 cites W1994212260 @default.
• W2025329937 cites W2005154155 @default.
• W2025329937 cites W2020374213 @default.
• W2025329937 cites W2029821549 @default.
• W2025329937 cites W2040565048 @default.
• W2025329937 cites W2041490190 @default.
• W2025329937 cites W2055512349 @default.
• W2025329937 cites W2080000513 @default.
• W2025329937 cites W2085124463 @default.
• W2025329937 cites W2094755933 @default.
• W2025329937 cites W2111953454 @default.
• W2025329937 cites W2120976938 @default.
• W2025329937 cites W2130290609 @default.
• W2025329937 cites W2146618453 @default.
• W2025329937 cites W2153804216 @default.
• W2025329937 cites W2159083249 @default.
• W2025329937 cites W4240449862 @default.
• W2025329937 cites W4252969106 @default.
• W2025329937 doi "https://doi.org/10.1016/j.nucmedbio.2009.01.010" @default.
• W2025329937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19423011" @default.
• W2025329937 hasPublicationYear "2009" @default.
• W2025329937 type Work @default.
• W2025329937 sameAs 2025329937 @default.
• W2025329937 citedByCount "11" @default.
• W2025329937 countsByYear W20253299372012 @default.
• W2025329937 countsByYear W20253299372013 @default.
• W2025329937 countsByYear W20253299372014 @default.
• W2025329937 countsByYear W20253299372015 @default.
• W2025329937 countsByYear W20253299372016 @default.
• W2025329937 countsByYear W20253299372019 @default.
• W2025329937 countsByYear W20253299372022 @default.
• W2025329937 crossrefType "journal-article" @default.
• W2025329937 hasAuthorship W2025329937A5001737851 @default.
• W2025329937 hasAuthorship W2025329937A5002173683 @default.
• W2025329937 hasAuthorship W2025329937A5006339259 @default.
• W2025329937 hasAuthorship W2025329937A5011091703 @default.
• W2025329937 hasAuthorship W2025329937A5033467158 @default.
• W2025329937 hasAuthorship W2025329937A5045566016 @default.
• W2025329937 hasAuthorship W2025329937A5079729400 @default.
• W2025329937 hasAuthorship W2025329937A5082078967 @default.
• W2025329937 hasAuthorship W2025329937A5086691038 @default.
• W2025329937 hasConcept C104317684 @default.
• W2025329937 hasConcept C126322002 @default.
• W2025329937 hasConcept C134018914 @default.
• W2025329937 hasConcept C161573976 @default.
• W2025329937 hasConcept C170493617 @default.
• W2025329937 hasConcept C185592680 @default.
• W2025329937 hasConcept C187345961 @default.
• W2025329937 hasConcept C2777866211 @default.
• W2025329937 hasConcept C2778938600 @default.
• W2025329937 hasConcept C2779306644 @default.
• W2025329937 hasConcept C2780152017 @default.
• W2025329937 hasConcept C502942594 @default.
• W2025329937 hasConcept C55493867 @default.
• W2025329937 hasConcept C63932345 @default.
• W2025329937 hasConcept C71924100 @default.
• W2025329937 hasConcept C86339819 @default.
• W2025329937 hasConcept C86803240 @default.
• W2025329937 hasConceptScore W2025329937C104317684 @default.
• W2025329937 hasConceptScore W2025329937C126322002 @default.
• W2025329937 hasConceptScore W2025329937C134018914 @default.
• W2025329937 hasConceptScore W2025329937C161573976 @default.
• W2025329937 hasConceptScore W2025329937C170493617 @default.
• W2025329937 hasConceptScore W2025329937C185592680 @default.
• W2025329937 hasConceptScore W2025329937C187345961 @default.
• W2025329937 hasConceptScore W2025329937C2777866211 @default.
• W2025329937 hasConceptScore W2025329937C2778938600 @default.
• W2025329937 hasConceptScore W2025329937C2779306644 @default.
• W2025329937 hasConceptScore W2025329937C2780152017 @default.
• W2025329937 hasConceptScore W2025329937C502942594 @default.
• W2025329937 hasConceptScore W2025329937C55493867 @default.
• W2025329937 hasConceptScore W2025329937C63932345 @default.
• W2025329937 hasConceptScore W2025329937C71924100 @default.

• next